Endotoxinemia and Vasoplegia Following Cardiothoracic Surgery With Cardiopulmonary Bypass (CPB)

Launched by UNIVERSITÄT MÜNSTER · Jun 20, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how a specific condition called endotoxinemia, which involves harmful substances in the blood, affects the likelihood of developing vasoplegia or vasoplegic shock after heart surgery. Vasoplegia is a state where the blood vessels become very relaxed, leading to low blood pressure and potential complications. The research focuses on patients who are undergoing cardiac surgery that requires a heart-lung machine (called cardiopulmonary bypass).

To participate in this study, individuals must be adults scheduled for this type of heart surgery and must provide written consent. However, some patients may not be eligible, including those who need emergency surgery, have certain chronic conditions, or are taking specific medications that suppress the immune system. Participants will be monitored after their surgery to see if they develop vasoplegia and how endotoxinemia may play a role in this. This study aims to improve our understanding of these complications to enhance patient care following cardiac operations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. adult patients undergoing cardiac surgery requiring CPB
• • 2. written informed consent
• Exclusion Criteria:
• • 1. emergency surgery in the context of acute coronary syndrome
• • 2. patients with chronic inflammatory diseases of the gut
• • 3. patients receiving immunosuppressive drugs
• • 4. patients with infectious endocarditis
• • 5. patients with sepsis
• • 6. patients with chronic kidney disease with estimated glomerular filtration rate (eGFR) \<20 ml/min/1,73m²
• • 7. persons with any kind of dependency on the investigator or employed by the institution responsible or investigator
• • 8. persons held in an institution by legal of official order -